Bayer Pharma Aktiengesellschaft

Bayer Aktiengesellschaft

Hoechst Aktiengesellschaft

Doris Gehring

Udo Albus

Klemens Lustig

Michael Hahn

Martina Delbeck

Björn Rosenstein

Thomas Ernst Müller

Karl Collins

Janine Nicolai

Moritz Beck-Broichsitter

Heinrich Meier

Niels Lindner

Luisella Toschi

Johanna Mosig

Heinrich Christian Englert

Dieter Mania

Erich F Paulus

Johanna Anlahr

Thomas Müller

Paul-Gerhard Kibat

Dehe Duan

Denghui Chen

Jianfei Yang

Hongkai Dang

Thomas Muller

Bjorn Rosenstein

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, such as compounds of the general formula (I): to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders

The present application relates to novel imidazopyridinyl- or imidazopyrimidinyl-substituted, bridged 1,4-diazepane derivatives of formula (I), to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring. Formula (I) in which the ring Q represents a bridged 1,4-diazepane cycle. 

Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors

The present invention relates to novel diazabicyclically substituted imidazo[1,2-a]pyrimidine derivatives, to methods for producing the same, to the use thereof either alone or in combinations for the treatment and/or prevention of diseases, as well as to their use for preparing medicaments for the treatment and/or prevention of diseases, especially for treatment and/or prevention of breathing disorders, including sleep-related breathing disorders such as obstructive and central sleep apnoea and snoring.

The present application relates to novel 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives, to processes for their preparation, to their use alone or in combinations for the treatment and/or prevention of diseases, and to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for treatment and/or prevention of respiratory disorders including, sleep-related respiratory disorders such as obstructive sleep apnoeas and central sleep apnoeas and snoring.

2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders

The present application relates to novel (2-phenylimidazo[1,2-a]pyridin-3-yl)methyl-substituted perhydropyrrolo[3,4-c]pyrrole derivatives, to methods for the preparation thereof, to the use thereof alone or in combinations for treatment and/or prevention of diseases, and to the use thereof for production of medicaments for treatment and/or prevention of diseases, especially for treatment and/or prevention of respiratory disorders including sleep-related respiratory disorders such as obstructive sleep apneas and central sleep apneas and snoring.

Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same

The invention relates to ethanol adducts of the compounds of the formula I ##STR1## to a process for their preparation and to their use as inhalants in diseases, in particular in asthma.

Ethanol adducts of 6-sulfonyl-substituted 3-hydroxy-chromans and their

Growing community of inventors

Kelkheim, Germany

Doris Gehring